MX2009012610A - Compuesto de tetrahidroisoquinolina 1-sustituido. - Google Patents

Compuesto de tetrahidroisoquinolina 1-sustituido.

Info

Publication number
MX2009012610A
MX2009012610A MX2009012610A MX2009012610A MX2009012610A MX 2009012610 A MX2009012610 A MX 2009012610A MX 2009012610 A MX2009012610 A MX 2009012610A MX 2009012610 A MX2009012610 A MX 2009012610A MX 2009012610 A MX2009012610 A MX 2009012610A
Authority
MX
Mexico
Prior art keywords
action
pain
abdominal
type
compound
Prior art date
Application number
MX2009012610A
Other languages
English (en)
Inventor
Kazuhiro Yokoyama
Makoto Inoue
Koichi Yonezawa
-Ichi Jun Shishikur
Takashi Ogiyama
Susumu Yamaki
Shuichirou Kakimoto
Hidetsugu Okada
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of MX2009012610A publication Critical patent/MX2009012610A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06—Peri-condensed systems

Abstract

Se pretende proporcionar un compuesto útil como un bloqueador del canal de Ca2+ de tipo N. Como resultado de estudios intensivos de compuestos que tienen una acción de bloqueo del canal de Ca2+ de tipo N, los presentes inventores encontraron que un compuesto de tetrahidroisoquinolina de la invención que tiene un sustituyente en la posición 1 tiene una acción de bloqueo del canal de Ca2+ de tipo N, una acción antinociceptiva sobre el dolor, una acción antineuropática sobre el dolor, una acción inhibidora del dolor abdominal y una acción mejoradora sobre el estreñimiento inducido por opioide, y por ello se ha llevado a cabo la invención. El compuesto de la invención se puede usar como una composición farmacéutica profiláctica y/o terapéutica para diversos dolores, tales como el dolor neuropático y el dolor nociceptivo, dolores de cabeza tales como migraña y dolor de cabeza en racimo, enfermedades del sistema nervioso central tales como ansiedad, depresión, epilepsia, derrame cerebral y síndrome de pierna inquieta, síntomas abdominales, tales como dolor abdominal y distensión abdominal, anormalidades en las heces tales como diarrea y estreñimiento, enfermedades del sistema digestivo tales como síndrome de intestino irritable, enfermedades urológicas, tales como vejiga hiperactiva y cistitis intersticial, y otros.
MX2009012610A 2007-05-22 2008-05-20 Compuesto de tetrahidroisoquinolina 1-sustituido. MX2009012610A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007135452 2007-05-22
PCT/JP2008/059287 WO2008143263A1 (ja) 2007-05-22 2008-05-20 １位置換テトラヒドロイソキノリン化合物

Publications (1)

Publication Number Publication Date
MX2009012610A true MX2009012610A (es) 2009-12-11

Family

ID=40031959

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012610A MX2009012610A (es) 2007-05-22 2008-05-20 Compuesto de tetrahidroisoquinolina 1-sustituido.

Country Status (16)

Country Link
US (1) US8263607B2 (es)
EP (1) EP2149560B1 (es)
JP (1) JP5299274B2 (es)
KR (1) KR101352709B1 (es)
CN (1) CN101679273B (es)
AU (1) AU2008254061B2 (es)
BR (1) BRPI0811145A2 (es)
CA (1) CA2687958A1 (es)
ES (1) ES2537803T3 (es)
IL (1) IL201987A (es)
MX (1) MX2009012610A (es)
PL (1) PL2149560T3 (es)
PT (1) PT2149560E (es)
RU (1) RU2468010C2 (es)
TW (1) TWI424845B (es)
WO (1) WO2008143263A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI425945B (zh) * 2007-05-28 2014-02-11 Seldar Pharma Inc 四氫異喹啉－１－酮衍生物或其鹽
CN101602708B (zh) * 2008-06-10 2012-11-21 江苏国华投资有限公司 芳烷醇哌啶衍生物及其在制备抗抑郁症药物中的应用
WO2011034051A1 (ja) * 2009-09-15 2011-03-24 参天製薬株式会社 新規環状スクアリン酸アミド誘導体
AU2013235487B2 (en) * 2012-03-23 2017-09-07 Memorial Sloan-Kettering Cancer Center Treatment of pancreatic and related cancers with 5-acyl-6,7-dihydrothieno[3,2-c]pyridines
FR3008976A1 (fr) 2013-07-23 2015-01-30 Servier Lab "nouveaux derives d'indolizine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent"
FR3008979B1 (fr) * 2013-07-23 2015-07-24 Servier Lab Nouveaux derives phosphates, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP4071140A1 (en) * 2015-12-24 2022-10-12 The Regents of The University of California Cftr regulators and methods of use thereof
EP4019501A1 (en) * 2015-12-24 2022-06-29 The Regents of the University of California Cftr regulators and methods of use thereof
WO2018054721A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054723A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018054711A1 (en) 2016-09-26 2018-03-29 Basf Se Pyridine compounds for controlling phytopathogenic harmful fungi
WO2018065182A1 (en) 2016-10-04 2018-04-12 Basf Se Reduced quinoline compounds as antifuni agents
WO2018073110A1 (en) 2016-10-20 2018-04-26 Basf Se Quinoline compounds as fungicides
US20190359589A1 (en) 2017-01-23 2019-11-28 Basf Se Fungicidal pyridine compounds
EP3606914A1 (en) 2017-04-06 2020-02-12 Basf Se Pyridine compounds
CA3073718A1 (en) 2017-08-24 2019-02-28 The Regents Of The University Of California Ocular pharmaceutical compositions
AU2020290485A1 (en) * 2019-06-12 2021-12-02 Arkuda Therapeutics Progranulin modulators and methods of using the same
CA3152485A1 (en) * 2019-09-30 2021-04-08 Yoshikazu Watanabe Azepane derivative

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3910915A (en) * 1973-07-23 1975-10-07 Searle & Co 1-Aryl-2-{8 (substituted amino)alkanoyl{9 -1,2,3,4-tetrahydroisoquinolines
CA2155448A1 (en) 1994-08-11 1996-02-12 Katerina Leftheris Inhibitors of farnesyl protein transferase
US7186726B2 (en) 1998-06-30 2007-03-06 Neuromed Pharmaceuticals Ltd. Preferentially substituted calcium channel blockers
WO2000075133A1 (fr) * 1999-06-03 2000-12-14 Yamanouchi Pharmaceutical Co., Ltd. Derives d'isoquinoline ou leurs sels
JPWO2001085693A1 (ja) 2000-05-11 2004-01-08 萬有製薬株式会社 Ｎ−アシルテトラヒドロイソキノリン誘導体
WO2002079189A2 (en) 2001-03-29 2002-10-10 Tanabe Seiyaku Co., Ltd. Spiroisoquinoline compounds, methods for their preparation and intermediates
JP2002363163A (ja) 2001-06-05 2002-12-18 Ono Pharmaceut Co Ltd ベンズアゼピン誘導体
JP4337138B2 (ja) 2001-08-31 2009-09-30 味の素株式会社 新規ジアリールアルケン誘導体及び新規ジアリールアルカン誘導体
AU2003218374A1 (en) 2002-03-28 2003-10-13 Neurogen Corporation Substituted tetrahydroisoquinolines as c5a receptor modulators
US20040214833A1 (en) 2003-04-11 2004-10-28 Boehringer Ingelheim International Gmbh Tricyclic heteroaromatic compounds
DE10316659A1 (de) 2003-04-11 2004-10-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tricyclische Heteroaromatische Verbindungen
JP4400566B2 (ja) 2003-06-12 2010-01-20 アステラス製薬株式会社 ベンズアミド誘導体又はその塩
WO2005005392A1 (en) 2003-07-07 2005-01-20 Ionix Pharmaceuticals Limited Azacyclic compounds as inhibitors of sensory neurone specific channels
TW200630337A (en) * 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof

Also Published As

Publication number Publication date
EP2149560B1 (en) 2015-05-13
TWI424845B (zh) 2014-02-01
AU2008254061A1 (en) 2008-11-27
EP2149560A4 (en) 2011-01-05
JP5299274B2 (ja) 2013-09-25
IL201987A (en) 2014-09-30
US8263607B2 (en) 2012-09-11
KR20100014570A (ko) 2010-02-10
EP2149560A1 (en) 2010-02-03
RU2468010C2 (ru) 2012-11-27
CA2687958A1 (en) 2008-11-27
WO2008143263A1 (ja) 2008-11-27
ES2537803T3 (es) 2015-06-12
US20100168154A1 (en) 2010-07-01
PL2149560T3 (pl) 2015-10-30
TW200914015A (en) 2009-04-01
CN101679273B (zh) 2013-03-06
JPWO2008143263A1 (ja) 2010-08-12
PT2149560E (pt) 2015-07-13
KR101352709B1 (ko) 2014-01-16
CN101679273A (zh) 2010-03-24
AU2008254061B2 (en) 2012-06-14
RU2009147451A (ru) 2011-06-27
IL201987A0 (en) 2010-06-16
BRPI0811145A2 (pt) 2014-12-23

Similar Documents

Publication Publication Date Title
MX2009012610A (es) Compuesto de tetrahidroisoquinolina 1-sustituido.
MY148144A (en) Synthetic peptide amides
MX2010003864A (es) Amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
MX2009004999A (es) Amidas de peptidos sinteticos y dimeros de las mismas.
MX2010003866A (es) Heteroaril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
NZ700881A (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2011007647A (es) Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
MX337990B (es) Metodos para la prevencion y tratamiento de isquemia cerebral.
MX2010003865A (es) Aril amidas utiles como inhibidores de canales de sodio dependientes de voltaje.
TN2016000238A1 (en) Tricyclic compounds as anticancer agents.
WO2007109230A3 (en) Nutrient compositions for the treatment and prevention of inflammation and disorders associated therewith
WO2012015758A3 (en) Methods of treating pain
EA201270012A1 (ru) Сублингвальный апоморфин
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2013036912A3 (en) Amido compounds as rorϒtmodulators and uses thereof
WO2008150477A3 (en) N-acetyl mannosamine as a therapeutic agent
MX347902B (es) Composicion para el alivio del dolor, que comprende un agonista selectivo de trpv1, y manufactura y usos de la misma.
MX347901B (es) Uso y composicion para tratar la demencia.
SG10201902370QA (en) Compositions and methods of use of phorbol esters
IL189298A0 (en) 3.5-disubstituted phenyl-piperidines as modulators of dopamine meurotransmission
EA201290305A1 (ru) Производные трициклического пиразоламина
WO2010033701A3 (en) Inhibitors of sphingosine kinase 1
IN2012DN01434A (es)
MX2014001966A (es) Inhibidores de la amida de acidos grasos (faah) restringidos perifericamente por bifenil metasustituido.
MX2011012140A (es) Ranolazina para el tratamiento de problemas del snc.

Legal Events

Date Code Title Description
FG Grant or registration